Atlas Trials

A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL

Clinical trial NCT03019185 · COMPLETED

Trial details

NCT number
NCT03019185
Sponsor
Biogen
Status
COMPLETED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Alport Syndrome
Start date
2017-03-02
Primary completion
2020-10-06
Enrollment
187

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.